Advertisement

U.S. Markets closed

S&P Futures
5,912.50
+6.50(+0.11%)
Dow Futures
43,571.00
+53.00(+0.12%)
Nasdaq Futures
20,509.00
+25.50(+0.12%)
Russell 2000 Futures
2,296.60
+5.40(+0.24%)
Crude Oil
69.52
+0.30(+0.43%)
Gold
2,739.10
+9.10(+0.33%)

ArriVent BioPharma, Inc. (AVBP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

29.16

+0.17

(+0.59%)

At close: 04:00PM EDT

29.16

0.00

(0.00%)

After hours:

04:02PM EDT

Loading interactive chart...

GlobeNewswire
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median duration of response not yet reached at time of analysis ArriVent to host virtual webinar on these interim analyses of Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC on September 9, 2024 at 4:30 pm ET NEWTOWN SQUARE, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or
Simply Wall St.
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...